Todays milestone establishes Ozempic as an option for patients to help address two critical aspects of managing type 2 diabetes, blood sugar control and cardiovascular risk reduction, in those with known heart disease. Changes to Rybelsus Prescribing Information The Rybelsus (semaglutide) prescribing information has been updated in section 14 (clinical studies) to include an analysis from the primary endpoint of the PIONEER 6 CVOT showing the hazard ratio for time to first three-component MACE (HR 0.79 [95% CI: 0.57, 1.11]).[5] In June 2019, Novo Nordisk initiated the SOUL CVOT in 9,642 adults with type 2 diabetes and established cardiovascular disease to further evaluate the cardiovascular effect of Rybelsus
Dehydration is a primary concern when diarrhea occurs, making fluid and electrolyte replacement an important part of symptom management
Anti-aging potential: Improved sleep and hormone regulation make DSIP attractive in longevity and wellness research
b , Data were replotted to generate a modified Schild plot and LSN3160440 K B (5.7 M) and (407) parameters were calculated using the allosteric Schild equation
Nat Rev Gastroenterol Hepatol (2014) 11:50614
FDA-approved therapeutic peptides have undergone extensive clinical trials with documented safety profiles